Pancreatic Cancer Clinical Trials
Pancreatic cancer clinical trials provide patients with access to promising new cancer treatments that aren’t yet readily available. Additionally, because clinical trials provide a reliable way to evaluate the effectiveness of newly discovered drugs and techniques in relation to those that are currently being used, they play a pivotal role in facilitating advances in the prevention and cure of cancer.
Of course, the health, safety and care of clinical trial participants always come first. Before any patients are enrolled in a trial, thorough investigations are conducted to ensure safety. Clinical research is a very exciting and important part of medicine. In fact, even today’s most widely recommended treatments for pancreatic cancer were once available to patients only through clinical trials.
Florida's Cancer Center of Excellence
Moffitt is a Cancer Center of Excellence by the state of Florida. The designation recognizes providers that exceed service standards and excel in providing quality, comprehensive and patient-coordinated care.
Moffitt Cancer Center is nationally recognized for its extensive research efforts and clinical trials, which have resulted in landmark advances in all aspects of cancer care. For instance, through our robust pancreatic cancer clinical trials program, Moffitt patients can be among the first to take advantage of promising new:
- Risk assessments
- Prevention, detection and diagnostic methods
- Chemotherapy drugs
- Surgical techniques
- Radiation therapy delivery techniques, immunotherapies, molecular therapies and other innovative treatment options
As the only National Cancer Institute-designated Comprehensive Cancer Center based in Florida, Moffitt is a well-established leader in cancer research. We have a multispecialty team of pancreatic cancer experts who work together to ensure that each patient receives the most appropriate and beneficial care. Depending on a patient’s individual circumstances, this might include a clinical trial or another advanced treatment option.
To learn more about the pancreatic cancer clinical trials available at Moffitt Cancer Center, call 1-813-745-6100 or 1-800-679-0775 (toll-free) or submit a clinical trials inquiry form online. Our clinical trial navigators can help you find out if a trial is right for you, and no referrals are necessary.
Helpful Links:
-
Clinical Trials
CLINICAL TRIAL 20105
Using Radiogenomics to Noninvasively Predict the Malignant Potential of Intraductal Papillary Mucinous Neoplasms (IPMNs) of the Pancreas and Uncover Hidden Biology
Condition: Gastrointestinal Tumor
Intervention:
CLINICAL TRIAL 21589
BASECAMP-1: An Observational Study Obtaining Solid Tumor Tissue from Subjects with Primary Surgical Resection and Leukapheresis for CAR T-Cell Therapy Manufacturing
Condition: Immunotherapy
Intervention:
CLINICAL TRIAL 21664
Phase 1b/3 z=Global, Randomized, Controlled, Open-Label Trial Comparing Treatment with RYZ101 to Standard of Care (SoC) Therapy in Subjects with Inoperable, Advanced, Somatostatin Receptor Expressing (SSTR+), Well-Differentiated Gastro-Enteropancreatic Neuroendocrine Tumors (GEP-NETs) that have Progressed Following Prior 177Lulabelled Somatostatin Analogue (177Lu-SSA) Therapy (ACTION-1).
Condition: Gastrointestinal Tumor
Intervention: Amino acids (); Granisetron (); Lanreotide (); Ondansetron (); RYZ101 (); Sunitinib (); Zofran (Ondansetron); everolimus (RAD001); octreotide LAR ()
CLINICAL TRIAL 21908
A Systematic Review of Supplements Applicable in Treatment of Pancreatic Adenocarcinoma with Action on the mTOR Complex
Condition: Gastrointestinal Tumor
Intervention:
CLINICAL TRIAL 22685
Phase 1/1B, Multicenter, Open-Label, Study of RMC-9805 in Participants with Advanced KRASG12D-Mutant Solid Tumors
Condition: Multiple
Intervention: RMC-6236 (Daraxonrasib); RMC-9805 (Zoldonrasib)
CLINICAL TRIAL 23088
Remote Exercise and Nutritional Prehabilitation for Pancreatic Cancer: A Randomized Pilot Study
Condition: Gastrointestinal Tumor
Intervention:
CLINICAL TRIAL 23448
A Phase 1 Trial Evaluating the Safety, Tolerability, PK, and Efficacy of QTX3034 in Patients with Solid Tumors with KRASG12D Mutation
Condition: Multiple
Intervention: Cemiplimab (); Cetuximab (); Erbitux (Cetuximab); Gemzar (gemcitabine); Nab-paclitaxel (Abraxane); Pembrolizumab (Keytruda); QTX3034 (); REGN2810 (Cemiplimab); gemcitabine (); mFOLFOX6 ()
CLINICAL TRIAL 23599
Phase 1a/1b Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of BBO-11818 in Subjects with Advanced KRAS Mutant Cancers
Condition: Multiple
Intervention: Alimta (Pemetrexed); BBO-10203 (); BBO-11818 (); Cetuximab (); Erbitux (Cetuximab); FOLFOX (); Gemzar (gemcitabine); NALIRIFOX (); Nab-paclitaxel (Abraxane); Paraplatin (carboplatin); Pembrolizumab (Keytruda); Pemetrexed (); carboplatin (); cisplatin (); gemcitabine (); mFOLFIRINOX (); mFOLFOX6 ()
CLINICAL TRIAL 23697
A Phase 1/1b, Open-label, Multicenter, First-in-human Dose Escalation and Dose Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of VVD-159642, a RAS-PI3KA Inhibitor, as a Single Agent and in Combination in Participants With Advanced Solid Tumors
Condition: Multiple
Intervention: AMG 510 (Sotorasib); GSK1120212 (Trametinib); Olomorasib (); Sotorasib (); Trametinib (); VVD-159642 ()
CLINICAL TRIAL 23713
A Phase 2/3, Multicenter, Randomized Open-Label study of Zanzalintinib vs Everolimus in Participants with Previously Treated, Unresectable, Locally Advanced or Metastatic Neuroendocrine Tumors
Condition: Gastrointestinal Tumor
Intervention: Zanubrutinib (); Zanzalintinib (); everolimus (RAD001)
CLINICAL TRIAL 23788
Artidis Nanomechanical Signature Profiling of Pancreatic Cancer Specimens (ANoPs)
Condition: Gastrointestinal Tumor
Intervention:
CLINICAL TRIAL 23929
A PHASE III RANDOMIZED TRIAL OF DOSE ESCALATED RADIATION IN LOCALLY ADVANCED PANCREAS CANCER (LAPC) PATIENTS (LAP100)
Condition: Gastrointestinal Tumor
Intervention:
CLINICAL TRIAL 23999
A Randomized Phase III Blinded Trial of Lanreotide for the Prevention of Postoperative Pancreatic Fistula
Condition: Gastrointestinal Tumor
Intervention: Lanreotide/Placebo ()
CLINICAL TRIAL 24073
A Phase 3, Multicenter, Prospective Open-Label Study to Evaluate the Diagnostic Performance of [18F] FAPI-74 PET/CT for the Detection of Metastatic Disease in Adults with Pancreatic Ductal Adenocarcinoma (FAPI-PRO)
Condition: Gastrointestinal Tumor
Intervention: [18F] FAPI-74 ()
CLINICAL TRIAL 24082
Using Automated Biochips to Assist in Specific Chemotherapy Selection in Pancreatic and Colorectal Cancer Patients
Condition: Gastrointestinal Tumor
Intervention:
CLINICAL TRIAL 24134
RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Monotherapy or Daraxonrasib Plus Gemcitabine and Nab-paclitaxel versus Gemcitabine and Nab-paclitaxel as a First-Line Treatment for Patients with Metastatic Pancreatic Adenocarcinoma
Condition: Gastrointestinal Tumor
Intervention: Daraxonrasib (); Gemzar (gemcitabine); Nab-paclitaxel (Abraxane); RMC-6236 (Daraxonrasib); gemcitabine ()
CLINICAL TRIAL 24169
A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Investigator Choice of Chemotherapy (modified FOLFIRINOX or Gemcitabine plus Nab-paclitaxel) with or without Zoldonrasib (RMC-9805) as First-line Treatment in Patients with Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma (RASolute 305)
Condition: Gastrointestinal Tumor
Intervention: 5-fluorouracil (); CPT-11 (irinotecan); Camptosar (irinotecan); Gemzar (gemcitabine); Nab-paclitaxel (Abraxane); Oxaliplatin (); Zoldonrasib/Placebo (); eloxatin (Oxaliplatin); gemcitabine (); irinotecan (); leucovorin ()
CLINICAL TRIAL 24170
A Phase 3, Randomized, Open-Label Study of Zoldonrasib (RMC-9805) Plus Daraxonrasib (RMC-6236) Versus Gemcitabine and Nab-Paclitaxel as First-Line Treatment in Patients With Metastatic KRAS G12D-Mutated Pancreatic Adenocarcinoma (RASolute 309)
Condition: Gastrointestinal Tumor
Intervention: Daraxonrasib (); Gemzar (gemcitabine); Nab-paclitaxel (Abraxane); RMC-6236 (Daraxonrasib); RMC-9805 (Zoldonrasib); Zoldonrasib (); gemcitabine ()
CLINICAL TRIAL 24243
A Phase 2, Open-label Study of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, as Monotherapy and with Cetuximab, in Patients with Metastatic KRAS G12D-Mutated Pancreatic Cancer (TARGET-D 201)
Condition: Gastrointestinal Tumor
Intervention: Cetuximab (); Erbitux (Cetuximab); VS-7375 ()
CLINICAL TRIAL 24299
A study of a mutant-selective inhibitor, CGT6297, in patients with advanced solid tumors harboring PIK3CA mutations
Condition: Multiple
Intervention: CGT6297 ()
CLINICAL TRIAL 24368
Expanded Access Program to Treat Patients with Previously Treated Metastatic Pancreatic Adenocarcinoma with Daraxonrasib
Condition: Gastrointestinal Tumor
Intervention: Daratumumab ()
CLINICAL TRIAL 24394
A Multi-center, Open-label, Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AN9025 in Participants with Advanced or Metastatic Solid Tumors Harboring RAS Mutations
Condition: Multiple
Intervention: AN9025 ()
Treatment